Genuinely
new
discovery
transcends
existing
knowledge.
Despite
this,
many
analyses
in
systems
neuroscience
neglect
to
test
speculative
hypotheses
against
benchmark
empirical
facts.
Some
of
these
inadvertently
use
circular
reasoning
present
knowledge
as
discovery.
Here,
I
discuss
that
this
problem
can
confound
key
results
and
estimate
it
has
affected
more
than
three
thousand
studies
network
over
the
last
decade.
suggest
future
reduce
by
limiting
evidence,
integrating
into
models,
rigorously
testing
proposed
discoveries
models.
conclude
with
a
summary
practical
challenges
recommendations.
Brain,
Год журнала:
2023,
Номер
146(11), С. 4414 - 4424
Опубликована: Июнь 6, 2023
Abstract
Excess
accumulation
and
aggregation
of
toxic
soluble
insoluble
amyloid-β
species
in
the
brain
are
a
major
hallmark
Alzheimer’s
disease.
Randomized
clinical
trials
show
reduced
deposits
using
monoclonal
antibodies
that
target
have
identified
MRI
signal
abnormalities
called
amyloid-related
imaging
(ARIA)
as
possible
spontaneous
or
treatment-related
adverse
events.
This
review
provides
comprehensive
state-of-the-art
conceptual
radiological
features,
detection
classification
challenges,
pathophysiology,
underlying
biological
mechanism(s)
risk
factors/predictors
associated
with
ARIA.
We
summarize
existing
literature
current
lines
evidence
ARIA-oedema/effusion
(ARIA-E)
ARIA-haemosiderosis/microhaemorrhages
(ARIA-H)
seen
across
anti-amyloid
therapeutic
development.
Both
forms
ARIA
may
occur,
often
early,
during
anti-amyloid-β
antibody
treatment.
Across
randomized
controlled
trials,
most
cases
were
asymptomatic.
Symptomatic
ARIA-E
occurred
at
higher
doses
resolved
within
3–4
months
upon
treatment
cessation.
Apolipoprotein
E
haplotype
dosage
factors
for
ARIA-H.
Presence
any
microhaemorrhage
on
baseline
increases
shares
many
clinical,
pathophysiological
features
disease
cerebral
amyloid
angiopathy.
There
is
great
need
to
conceptually
link
evident
synergistic
interplay
such
conditions
allow
clinicians
researchers
further
understand,
deliberate
investigate
combined
effects
these
multiple
processes.
Moreover,
this
article
aims
better
assist
(either
observed
via
symptoms
visually
MRI),
management
based
appropriate
use
recommendations,
general
preparedness
awareness
when
well
fundamental
understanding
various
development
their
risks
To
facilitate
practice,
we
recommend
implementation
standardized
protocols
rigorous
reporting
standards.
With
availability
approved
therapies
clinic,
monitoring
required
effectively
detect,
monitor,
manage
real-world
settings.
European journal of medical research,
Год журнала:
2024,
Номер
29(1)
Опубликована: Янв. 5, 2024
This
review
article
explores
the
dynamic
field
of
radiopharmaceuticals,
where
innovative
developments
arise
from
combining
radioisotopes
and
pharmaceuticals,
opening
up
exciting
therapeutic
possibilities.
The
in-depth
exploration
covers
targeted
drug
delivery,
delving
into
passive
targeting
through
enhanced
permeability
retention,
as
well
active
using
ligand-receptor
strategies.
also
discusses
stimulus-responsive
release
systems,
which
orchestrate
controlled
release,
enhancing
precision
effectiveness.
A
significant
focus
is
placed
on
crucial
role
radiopharmaceuticals
in
medical
imaging
theranostics,
highlighting
their
contribution
to
diagnostic
accuracy
image-guided
curative
interventions.
emphasizes
safety
considerations
strategies
for
mitigating
side
effects,
providing
valuable
insights
addressing
challenges
achieving
precise
delivery.
Looking
ahead,
nanoparticle
formulations
cutting-edge
innovations
next-generation
showcasing
potential
applications.
Real-world
examples
are
presented
case
studies,
including
use
radiolabelled
antibodies
solid
tumors,
peptide
receptor
radionuclide
therapy
neuroendocrine
intricate
management
bone
metastases.
concluding
perspective
envisions
future
trajectory
anticipating
a
harmonious
integration
medicine
artificial
intelligence.
vision
foresees
an
era
aligns
seamlessly
with
scientific
advancements,
ushering
new
epoch
marked
by
fusion
resonance
visionary
progress.
Trends in Pharmacological Sciences,
Год журнала:
2023,
Номер
44(7), С. 411 - 424
Опубликована: Май 31, 2023
Artificial
intelligence
(AI)-based
predictive
models
are
being
used
to
foster
a
precision
medicine
approach
treat
complex
chronic
diseases
such
as
autoimmune
and
autoinflammatory
disorders
(AIIDs).
In
the
past
few
years
first
of
systemic
lupus
erythematosus
(SLE),
primary
Sjögren
syndrome
(pSS),
rheumatoid
arthritis
(RA)
have
been
produced
by
molecular
profiling
patients
using
omic
technologies
integrating
data
with
AI.
These
advances
confirmed
pathophysiology
involving
multiple
proinflammatory
pathways
also
provide
evidence
for
shared
dysregulation
across
different
AIIDs.
I
discuss
how
stratify
patients,
assess
causality
in
pathophysiology,
design
drug
candidates
silico,
predict
efficacy
virtual
patients.
By
relating
individual
patient
characteristics
predicted
properties
millions
candidates,
these
can
improve
management
AIIDs
through
more
personalized
treatments.
Pharmaceutics,
Год журнала:
2024,
Номер
16(8), С. 1076 - 1076
Опубликована: Авг. 16, 2024
Preclinical
and
clinical
studies
have
demonstrated
that
precision
therapy
has
a
broad
variety
of
treatment
applications,
making
it
an
interesting
research
topic
with
exciting
potential
in
numerous
sectors.
However,
major
obstacles,
such
as
inefficient
unsafe
delivery
systems
severe
side
effects,
impeded
the
widespread
use
medicine.
The
purpose
drug
(DDSs)
is
to
regulate
time
place
release
action.
They
aid
enhancing
equilibrium
between
medicinal
efficacy
on
target
hazardous
effects
off
target.
One
promising
approach
biomaterial-assisted
biotherapy,
which
takes
advantage
biomaterials’
special
capabilities,
high
biocompatibility
bioactive
characteristics.
When
administered
via
different
routes,
molecules
deal
biological
barriers;
DDSs
help
them
overcome
these
hurdles.
With
their
adaptable
features
ample
packing
capacity,
biomaterial-based
allow
for
targeted,
localised,
prolonged
medications.
Additionally,
they
are
being
investigated
more
controlling
interface
host
tissue
implanted
biomedical
materials.
This
review
discusses
innovative
nanoparticle
designs
non-personalised
applications
improve
therapies.
We
prioritised
design
trends
address
heterogeneous
barriers,
because
we
believe
intelligent
can
patient
outcomes
by
enabling
improving
general
efficacy.
additionally
reviewed
most
recent
literature
biomaterials
used
biotherapy
vaccine
development,
covering
delivery,
stem
cell
therapy,
gene
other
similar
fields;
also
addressed
difficulties
future
biotherapies.
Science Bulletin,
Год журнала:
2024,
Номер
69(10), С. 1536 - 1555
Опубликована: Март 6, 2024
Recent
advances
in
open
neuroimaging
data
are
enhancing
our
comprehension
of
neuropsychiatric
disorders.
By
pooling
images
from
various
cohorts,
statistical
power
has
increased,
enabling
the
detection
subtle
abnormalities
and
robust
associations,
fostering
new
research
methods.
Global
collaborations
imaging
have
furthered
knowledge
neurobiological
foundations
brain
disorders
aided
imaging-based
prediction
for
more
targeted
treatment.
Large-scale
magnetic
resonance
initiatives
driving
innovation
analytics
supporting
generalizable
psychiatric
studies.
We
also
emphasize
significant
role
big
understanding
neural
mechanisms
early
identification
precise
treatment
However,
challenges
such
as
harmonization
across
different
sites,
privacy
protection,
effective
sharing
must
be
addressed.
With
proper
governance
science
practices,
we
conclude
with
a
projection
how
large-scale
resources
could
revolutionize
diagnosis,
selection,
outcome
prediction,
contributing
to
optimal
health.
